Skip to main content

Day: August 18, 2022

Molecular Partners Half Year 2022 News Release and Investor Call Details

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summarizing its highlights and financial results for the first half-year of 2022, followed by an analyst & investor call the following day. Please see more details here: Release date and timeAugust 25, 2022, 4:30 pm ET (10:30 pm CET)Call Details:August 26, 2022, 8:00 am ET (2:00 pm CET)The half year 2022 results presentation will be webcast live and will be made available on the Company’s website under the investor section. The replay will be available for 90 days following the presentation. In order to register for the H1 2022 conference call on...

Continue reading

Multitude SE publishes H1 2022 results

Multitude SE publishes H1 2022 results Helsinki, 18 August 2022 – Multitude SE (ISIN: FI4000106299, WKN: A1W9NS) (“Multitude” or the “Group”) announces unaudited results for the half year ended 30 June 2022 (“H1 2022”). Financial HighlightsRevenue increased by EUR 2.2m compared to H1 2021, despite headwind from market environmentStrong lending portfolio growth over several quarters +23.1% y-o-y EBIT, PBT, and after-tax profit amounted to EUR 12.0m, EUR 2.9m, and EUR 2.0mKey Figures, EUR million H1 2022 H1 2021*Revenue 107.0 104.8Profit before interests and taxes (EBIT) 12.0 15.7Profit before tax 2.9 6.4Net profit from continuing operations 2.0 4.9Net Profit (loss) 2.0 2.4Earnings per share, basic, continuing operations (EUR)       0.03 0.23Earnings per share, attributable to the ordinary equity...

Continue reading

Kinepolis sees cinema attendance recover further and is regaining financial strength

Kinepolis sees cinema attendance recover further and is regaining financial strength Regulatory release 18 August 2022, 7 a.m. Kinepolis recorded a strong recovery in its operating result and free cash flow in the first half of 2022. The Group saw a progressive recovery in cinema attendance in all countries, with countries that initially lagged behind now catching up. The summer holiday started promisingly, but was then plagued by the heat wave. Kinepolis welcomed five times more visitors in the first half of 2022 than in the first half of 2021, or 77.2% of visitors compared to the same period in 2019. While Covid measures were still in force in most countries in the first quarter, with the Dutch and some of the Canadian cinemas remaining closed until the end of January, all cinemas were free of measures in the second quarter. In the month...

Continue reading

13/2022・Trifork Group – Report of the quarter ending 30 June 2022

Company announcement no. 13 / 2022 Schindellegi, Switzerland – 18 August 2022 Trifork Group – Report of the second quarter ending 30 June 2022 Trifork Group reports stable organic revenue growth in Q2 2022 and confirms full year guidance Second quarter of 2022Revenue of Trifork Group (“Trifork”) in the second quarter of 2022 was EURm 45.9, an increase of 14.9% compared to the same period in 2021. Revenue grew organically by 17.8% (adjusted for deconsolidation of Dawn Health) compared to the same period in 2021 and was driven by organic growth from Digital Health and Cyber Protection in the Build and Run sub-segments. Trifork segment adjusted EBITDA in Q2 2022 was EURm 6.4 equal to an adjusted EBITDA-margin of 13.8% compared to 18.4% in Q2 2021.This decrease in margins was to a large degree a result of a EURm 0.5 write-off in the...

Continue reading

Novaturas group financials for 6M 2022: high fuel prices effected company’ profitability

Novaturas group started 2022 with strong sales results. The income generated during the first half of 2022 surpassed both the results for the same period in 2021 and the pre-pandemic results in 2019. The company generated EUR 92M of income during the first half-year of 2022 and served 128K travelers throughout the entire group. However, rapidly increasing aviation fuel prices had a negative impact on profitability figures and therefore the EBITDA was negative and reached EUR 750K. “In order to manage the impact of increased aviation prices, we applied a fuel insurance strategy during the second quarter of this year, which proved to be effective – financial derivatives allowed us to generate EUR 103K of profit. Nevertheless, we did not insure the entire scheduled flight program and the aviation fuel prices continued growing significantly...

Continue reading

UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the pricing of an upsized underwritten public offering of 64,285,714 shares of its common stock and accompanying warrants to purchase up to 64,285,714 shares of common stock at a combined public offering price of $0.70 per share and accompanying warrant. The warrants have an exercise price of $0.85 per share, are exercisable immediately, and will expire five years following the date of issuance. The gross proceeds to UNITY from the offering are expected to be approximately $45.0 million, before underwriting discounts and commissions and offering costs. All of the securities are being offered by UNITY. The offering...

Continue reading

Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection

— Additional indications: treatment for Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis and pediatric Crohn’s disease SHANGHAI, China, Aug. 17, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the Company has received an Acceptance Notice issued by the National Medical Products Administration (“NMPA”). The supplemental application for additional indications of the company’s adalimumab injection (project code: UBP1211, trade name: 君迈康), including the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children...

Continue reading

Ottawa Bancorp, Inc. Announces Second Quarter 2022 Results and Cash Dividend

OTTAWA, Ill., Aug. 17, 2022 (GLOBE NEWSWIRE) — Ottawa Bancorp, Inc. (the “Company”) (OTCQX: OTTW), the holding company for OSB Community Bank (the “Bank”), announced net income of $0.7 million, or $0.28 per basic and diluted common share, for the three months ended June 30, 2022, compared to net income of $0.7 million, or $0.26 per basic and diluted common share for the three months ended June 30, 2021. For the six months ended June 30, 2022, the Company announced net income of $1.6 million, or $0.59 per basic and diluted common share, compared to net income of $1.3 million, or $0.46 per basic and diluted common share, for the six months ended June 30, 2021. During the second quarter of 2022, the Company continued to grow the loan portfolio even though loan originations have tapered off significantly throughout 2022. The loan portfolio,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.